What is the appropriate clindamycin palmitate (75 mg/5 mL) dosage and treatment duration for a 63‑lb (≈28.6 kg) child with a possible tick bite and cellulitis?

Clindamycin Palmitate Dosing for Cellulitis in a 63-lb Child

For a 63-lb (28.6 kg) child with cellulitis, administer clindamycin palmitate 30-40 mg/kg/day divided into 3 doses, which equals approximately 286-381 mg per dose (or 9.5-12.7 mL of the 75mg/5mL suspension) three times daily for 5-7 days.

Dosing Calculation and Rationale

The IDSA guidelines 1 specify that for pediatric skin and soft tissue infections (SSTIs), clindamycin should be dosed at:

• 30-40 mg/kg/day divided into 3 doses for oral administration
• For MRSA coverage specifically: 30-40 mg/kg/day in 3 divided doses

For your 28.6 kg patient:

• Low end: 30 mg/kg/day = 858 mg/day ÷ 3 = 286 mg per dose (9.5 mL three times daily)
• High end: 40 mg/kg/day = 1,144 mg/day ÷ 3 = 381 mg per dose (12.7 mL three times daily)

I recommend starting at 10-11 mL (300-330 mg) three times daily, which provides adequate coverage while remaining within guideline parameters.

Treatment Duration

Duration should be 5-7 days based on clinical response 1. Recent pediatric data 2 demonstrates that 7 days of clindamycin for purulent SSTIs is optimal and evidence-based. The IDSA guidelines note that duration depends on clinical response, with 7 days being standard for most uncomplicated cases 1.

Important Considerations for Tick Bite Context

Critical Caveat About Tick Bites

If this is truly a tick bite with concern for tick-borne illness (not just secondary cellulitis), clindamycin is NOT appropriate. Tick-borne diseases like Lyme disease, Rocky Mountain spotted fever, or ehrlichiosis require doxycycline, even in children. However, if the cellulitis is a secondary bacterial infection around a tick bite site, clindamycin is appropriate.

When Clindamycin is Appropriate

Clindamycin provides excellent coverage for:

• MRSA (community-acquired strains common in skin infections)
• Streptococcal species (including Group A Strep)
• MSSA (methicillin-susceptible Staph aureus)

The IDSA guidelines 1 note that clindamycin is an "important option for children" and covers both purulent and non-purulent cellulitis when MRSA is suspected.

Pharmacokinetic Support

The FDA label 3 confirms that pediatric patients weighing 50-100 lbs receiving doses in the 8-16 mg/kg/day range achieve:

• Peak serum levels of 2.46-3.79 mcg/mL by the fifth dose
• Serum levels exceeding MICs for most indicated organisms for at least 6 hours
• Rapid hydrolysis of palmitate ester to active clindamycin

Your dosing of 30-40 mg/kg/day falls well within established safe and effective ranges.

Monitoring and Safety

Watch for these adverse effects 3:

• Diarrhea (most common; if severe or bloody, consider C. difficile)
• Rash (occurred in 15% of children in one study 4)
• Gastrointestinal upset

Clinical response should be evident within 48-72 hours. If no improvement or worsening occurs:

• Consider incision and drainage if abscess present
• Obtain cultures if not already done
• Consider alternative diagnosis (including tick-borne illness)
• Reassess antibiotic choice based on local resistance patterns

Common Pitfalls to Avoid

1. Don't underdose: Using only 25 mg/kg/day (the lower IV dosing) for oral therapy may be inadequate
2. Don't extend duration unnecessarily: 5-7 days is sufficient for uncomplicated cellulitis 2
3. Don't miss tick-borne disease: If systemic symptoms (fever, headache, myalgias) are prominent, reconsider the diagnosis
4. Don't ignore treatment failure: If no improvement by 48-72 hours, the patient needs reassessment, not just continued antibiotics